LNAI - Enochian Biosciences Inc

0.3615
-0.020   -5.394%

Share volume: 91,821
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.31%

PREVIOUS CLOSE
CHG
CHG%
$0.38
-0.02
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
58%
Profitability 58%
Dept financing 50%
Liquidity 1%
Performance 75%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.37%
1 Month
-45.43%
3 Months
-73.80%
6 Months
92.19%
1 Year
-57.17%
2 Year
-86.41%
Key data
Stock price
$0.36
P/E Ratio 
0.00
DAY RANGE
$0.36 - $0.40
EPS 
$0.01
52 WEEK RANGE
$0.12 - $1.66
52 WEEK CHANGE
-$55.77
MARKET CAP 
20.660 M
YIELD 
N/A
SHARES OUTSTANDING 
24.187 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
2.35
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$181,934
AVERAGE 30 VOLUME 
$303,020
Company detail
CEO: Mark R. Dybul
Region: US
Website: enochianbio.com
Employees: 20
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Enochian Biosciences, Inc. engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment.

Recent news